Results 71 to 80 of about 2,552 (169)
Abigail Tebboth,1 Andrew Ternouth,1 Nuria Gonzalez-Rojas2 1Boehringer Ingelheim Ltd., Bracknell, UK; 2Boehringer Ingelheim GmBH, Ingelheim, Germany Objective: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic ...
Tebboth A, Ternouth A, Gonzalez-Rojas N
doaj
Cost-utility of tiotropium in patients with severe asthma
Summary Add-on therapy with tiotropium was cost-effective when added to usual care in patients who remain uncontrolled despite treatment with medium or high-dose ICS/LABA in a middle-income country.
Jefferson Antonio Buendía +1 more
doaj +1 more source
Anoop Prakash,1 K Suresh Babu,2 Jaymin B Morjaria1,31Department of Respiratory Medicine, Castle Hill Hospital, Cottingham, 2Department of Respiratory Medicine, Queen Alexandra Hospital, Cosham, Portsmouth, 3Department of Academic Respiratory Medicine ...
Prakash A, Babu KS, Morjaria JB
doaj
Andreas Karabis,1 Leandro Lindner,2 Michelle Mocarski,3 Eline Huisman,1 Andrew Greening4 1MAPI Consultancy, AX Houten, The Netherlands; 2Almirall SA, Barcelona, Spain; 3Health Economics and Outcomes Research, Forest Research Institute, Jersey City, NJ ...
Karabis A +4 more
doaj
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry. [PDF]
Puggioni F +9 more
europepmc +1 more source
Role of Tiotropium as Step Up Therapy for Asthma
Background: To determine the role of Tiotropium as step up therapy for patients with uncontrolled asthma. Methods: In this case control study 130 patients, with diagnosis of bronchial asthma for at least 01 year and presently on step 4 treatment and ...
Muhammad Usman Ullah
doaj
Jutta Beier,1 Robert Mroz,2,3 Anne-Marie Kirsten,4 Ferran Chuecos,5 Esther Garcia Gil5 1insaf Respiratory Research Institute, Wiesbaden, Germany; 2Centrum Medycyny Oddechowej, 3Medical University of Białystok, Białystok, Poland; 4Pulmonary Research ...
Beier J +4 more
doaj
Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide, and the reduced activities of daily living, productivity and disability explain a significant economic and social damage.
A. U. Kulikov, I. A. Komarov
doaj
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
Roland Buhl,1 Donald Banerji21Pulmonary Department, Mainz University Hospital, Mainz, Germany; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAbstract: Bronchodilators are central in the symptomatic management of chronic obstructive ...
Buhl R, Banerji D
doaj

